Matthew E Levy1, Anne K Monroe1, Michael A Horberg2, Debra A Benator3,4, Sherry Molock5, Rupali K Doshi1, Lindsey Powers Happ1, Amanda D Castel1. 1. Department of Epidemiology, Milken Institute School of Public Health at the George Washington University, Washington, DC. 2. Mid-Atlantic Permanente Research Institute, Kaiser Permanente Mid-Atlantic States, Rockville, MD. 3. Infectious Diseases Section, Veterans Affairs Medical Center, Washington, DC. 4. George Washington University School of Medicine and Health Sciences, Washington, DC. 5. Department of Psychology, The George Washington University, Washington, DC.
Abstract
OBJECTIVE: To evaluate associations of mood, anxiety, stress-/trauma-related, and psychotic disorders, both treated and untreated, with duration of unsuppressed HIV viral load (VL) among persons living with HIV (PLWH). SETTING: The DC Cohort, an observational clinical cohort of PLWH followed from 2011 to 2018 at 14 sites in Washington, DC. METHODS: Among PLWH ≥18 years old who received primary care at their HIV clinic, we determined in a time-updated manner whether participants had diagnoses and pharmacologic prescriptions for mood, anxiety, stress-/trauma-related, and/or psychotic disorders. Associations between psychiatric disorders/treatments and the proportion of subsequent days with VL ≥200 copies/mL were assessed using multivariable Poisson regression with generalized estimating equations. RESULTS: Among 5904 participants (median age 51; 70% men; 82% Black), 45% had ≥1 psychiatric disorder, including 38% with mood disorders (50% treated), 18% with anxiety or stress-/trauma-related disorders (64% treated), and 4% with psychotic disorders (52% treated). Untreated major depressive disorder (adjusted rate ratio = 1.17; 95% confidence interval: 1.00 to 1.37), untreated other/unspecified depressive disorder (1.23; 1.01 to 1.49), untreated bipolar disorder (1.39; 1.15 to 1.69), and treated bipolar disorder (1.25; 1.02 to 1.53) (vs. no mood disorder) predicted more time with VL ≥200 copies/mL. Treated anxiety disorders (vs. no anxiety disorder) predicted less time (0.78; 0.62 to 0.99). Associations were weaker and nonsignificant for treated depressive disorders (vs. no mood disorder) and untreated anxiety disorders (vs. no anxiety disorder). CONCLUSIONS: PLWH with depressive and bipolar disorders, particularly when untreated, spent more time with unsuppressed VL than PLWH without a mood disorder. Treatment of mood disorders may be important for promoting sustained viral suppression.
OBJECTIVE: To evaluate associations of mood, anxiety, stress-/trauma-related, and psychotic disorders, both treated and untreated, with duration of unsuppressed HIV viral load (VL) among persons living with HIV (PLWH). SETTING: The DC Cohort, an observational clinical cohort of PLWH followed from 2011 to 2018 at 14 sites in Washington, DC. METHODS: Among PLWH ≥18 years old who received primary care at their HIV clinic, we determined in a time-updated manner whether participants had diagnoses and pharmacologic prescriptions for mood, anxiety, stress-/trauma-related, and/or psychotic disorders. Associations between psychiatric disorders/treatments and the proportion of subsequent days with VL ≥200 copies/mL were assessed using multivariable Poisson regression with generalized estimating equations. RESULTS: Among 5904 participants (median age 51; 70% men; 82% Black), 45% had ≥1 psychiatric disorder, including 38% with mood disorders (50% treated), 18% with anxiety or stress-/trauma-related disorders (64% treated), and 4% with psychotic disorders (52% treated). Untreated major depressive disorder (adjusted rate ratio = 1.17; 95% confidence interval: 1.00 to 1.37), untreated other/unspecifieddepressive disorder (1.23; 1.01 to 1.49), untreated bipolar disorder (1.39; 1.15 to 1.69), and treated bipolar disorder (1.25; 1.02 to 1.53) (vs. no mood disorder) predicted more time with VL ≥200 copies/mL. Treated anxiety disorders (vs. no anxiety disorder) predicted less time (0.78; 0.62 to 0.99). Associations were weaker and nonsignificant for treated depressive disorders (vs. no mood disorder) and untreated anxiety disorders (vs. no anxiety disorder). CONCLUSIONS: PLWH with depressive and bipolar disorders, particularly when untreated, spent more time with unsuppressed VL than PLWH without a mood disorder. Treatment of mood disorders may be important for promoting sustained viral suppression.
Authors: B M Celesia; L Nigro; M R Pinzone; C Coco; R La Rosa; F Bisicchia; S Mavilla; M Gussio; G Pellicanò; V Milioni; F Palermo; R Russo; M T Mughini; F Martellotta; R Taibi; B Cacopardo; G Nunnari Journal: Eur Rev Med Pharmacol Sci Date: 2013 Impact factor: 3.507
Authors: Brian W Pence; Bradley N Gaynes; Julie L Adams; Nathan M Thielman; Amy D Heine; Michael J Mugavero; Teena McGuinness; James L Raper; James H Willig; Kristen G Shirey; Michelle Ogle; Elizabeth L Turner; E Byrd Quinlivan Journal: AIDS Date: 2015-09-24 Impact factor: 4.177
Authors: S Clement; O Schauman; T Graham; F Maggioni; S Evans-Lacko; N Bezborodovs; C Morgan; N Rüsch; J S L Brown; G Thornicroft Journal: Psychol Med Date: 2014-02-26 Impact factor: 7.723
Authors: Rushina Cholera; Brian W Pence; Angela M Bengtson; Heidi M Crane; Katerina Christopoulos; Steven R Cole; Rob Fredericksen; Bradley N Gaynes; Amy Heine; W Christopher Mathews; Matthew J Mimiaga; Richard Moore; Sonia Napravnik; Conall O'Clerigh; Steven Safren; Michael J Mugavero Journal: PLoS One Date: 2017-01-26 Impact factor: 3.240
Authors: Angela M Bengtson; Brian W Pence; Heidi M Crane; Katerina Christopoulos; Rob J Fredericksen; Bradley N Gaynes; Amy Heine; W Christopher Mathews; Richard Moore; Sonia Napravnik; Steven Safren; Michael J Mugavero Journal: PLoS One Date: 2016-08-11 Impact factor: 3.240
Authors: Hilary Goldhammer; Linda G Marc; Nicole S Chavis; Demetrios Psihopaidas; Massah Massaquoi; Sean Cahill; Hannah Bryant; Beth Bourdeau; Kenneth H Mayer; Stacy M Cohen; Alex S Keuroghlian Journal: Open Forum Infect Dis Date: 2022-07-26 Impact factor: 4.423